VBIV vs. RLYB, ALRN, ELDN, BTAI, CKPT, VHAQ, AFMD, LTRN, MNOV, and LPTX
Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include Rallybio (RLYB), Aileron Therapeutics (ALRN), Eledon Pharmaceuticals (ELDN), BioXcel Therapeutics (BTAI), Checkpoint Therapeutics (CKPT), Viveon Health Acquisition (VHAQ), Affimed (AFMD), Lantern Pharma (LTRN), MediciNova (MNOV), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
VBI Vaccines (NASDAQ:VBIV) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
VBI Vaccines received 467 more outperform votes than Rallybio when rated by MarketBeat users. Likewise, 74.40% of users gave VBI Vaccines an outperform vote while only 73.33% of users gave Rallybio an outperform vote.
In the previous week, VBI Vaccines had 2 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for VBI Vaccines and 2 mentions for Rallybio. Rallybio's average media sentiment score of 0.93 beat VBI Vaccines' score of 0.72 indicating that Rallybio is being referred to more favorably in the news media.
12.3% of VBI Vaccines shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 10.4% of VBI Vaccines shares are owned by company insiders. Comparatively, 7.4% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Rallybio has a consensus price target of $12.20, indicating a potential upside of 630.54%. Given Rallybio's higher probable upside, analysts clearly believe Rallybio is more favorable than VBI Vaccines.
Rallybio has a net margin of 0.00% compared to VBI Vaccines' net margin of -881.79%. Rallybio's return on equity of -66.59% beat VBI Vaccines' return on equity.
VBI Vaccines has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.63, meaning that its stock price is 263% less volatile than the S&P 500.
Rallybio has lower revenue, but higher earnings than VBI Vaccines.
Summary
VBI Vaccines and Rallybio tied by winning 7 of the 14 factors compared between the two stocks.
Get VBI Vaccines News Delivered to You Automatically
Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VBI Vaccines Competitors List
Related Companies and Tools
